Drugs / Diosmin / Hesperidin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07293767 | Nov 2024 → Jan 2026 overdue | fibromyalgia | Ain Shams University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diosmin / Hesperidin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07293767 ↗ |
| Known as | Daflon | “Diosmin / Hesperidin (Daflon)” NCT07293767 ↗ |
| Route | Oral | “Diosmin / Hesperidin (Daflon) 500 mg will be taken once daily for 12 weeks with the standard treatment” NCT07293767 ↗ |